| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.03. | Bolt Projects Holdings, Inc. - 15-12G, Securities registration termination | - | SEC Filings | ||
| 27.02. | Bolt Projects Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.02. | Bolt Projects to delist from Nasdaq, deregister with SEC | 3 | Seeking Alpha | ||
| 19.02. | Bolt Projects Holdings Announces Delisting From Nasdaq and SEC Deregistration | 1.130 | Business Wire | BERKELEY, Calif.--(BUSINESS WIRE)--Bolt Projects Holdings, Inc. (OTC Pink: BSLK, BSLKW), a developer of biomaterials for the beauty and personal care industry, today announced that its Board of Directors... ► Artikel lesen | |
| BOLT PROJECTS Aktie jetzt für 0€ handeln | |||||
| 05.01. | NASDAQ: Delisting von Bolt Projects Holdings nach Nichterfüllung der Eigenkapitalanforderungen | 1 | Investing.com Deutsch | ||
| 05.01. | Bolt Projects Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.12.25 | Bolt Projects Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.25 | Bolt Projects Holdings GAAP EPS of -$2.70, revenue of $0.37M | 1 | Seeking Alpha | ||
| 12.11.25 | Bolt Projects Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.10.25 | Bolt Projects announces prelim Q3 results and updates 2025 guidance | 1 | Seeking Alpha | ||
| 17.10.25 | Bolt Projects Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.08.25 | Pre-market Movers: Sonoma Pharmaceuticals, Bolt Projects, Ibotta, TeraWulf, 180 Life Sciences | 883 | AFX News | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green Sonoma Pharmaceuticals, Inc. (SNOA) is up over... ► Artikel lesen | |
| 17.07.25 | Pre-market Movers: Volcon, Bolt Projects, 22nd Century Group, Above Food Ingredients, Windtree Therapeutics | 1.056 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.25 A.M. ET).In the Green Volcon, Inc. (VLCN) is up over 161% at $24.11.
Bolt... ► Artikel lesen | |
| 30.05.25 | Pre-market Movers: Bolt Projects, Basel Medical Group, Red Robin Gourmet Burgers, LZ Technology, Medicus Pharma | 1.334 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 06.55 A.M. ET).In the Green Bolt Projects Holdings, Inc. (BSLK) is up over 114%... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EDITAS MEDICINE | 2,430 | -3,19 % | Editas Medicine, Inc. - 8-K, Current Report | ||
| SOL GLOBAL INVESTMENTS | 0,020 | 0,00 % | XFRA 9SB0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSOL GLOBAL INVESTM.... ► Artikel lesen | |
| TRINITY BIOTECH | 0,700 | +0,34 % | Trinity Biotech plc: Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture Prostate Cancer Test | Test Now Incorporates Enhanced Machine Learning Risk Prediction Algorithm Plans Underway to Commercialise Testing Service Through Trinity Biotech's New York Reference Laboratory DUBLIN and NEW YORK... ► Artikel lesen | |
| FATE THERAPEUTICS | 1,054 | -0,75 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates | Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge Four systemic sclerosis... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 8,360 | +1,64 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| OVID THERAPEUTICS | 2,400 | +1,69 % | Ovid Therapeutics: H.C. Wainwright verdoppelt Kursziel auf 4 $ | ||
| CABALETTA BIO | 3,140 | -1,26 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Rese-cel myositis BLA submission on track for 2027 based on a 17-patient, single arm registrational cohort design, including an outpatient dosing option No-preconditioning program enrolling in lupus... ► Artikel lesen | |
| LONGEVERON | 1,165 | +3,10 % | Longeveron Inc. - 8-K, Current Report | ||
| VOR BIOPHARMA | 15,460 | -0,90 % | Stifel reiterates Vor Biopharma stock rating on drug potential | ||
| QIAGEN | 35,045 | +0,04 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| IMMUNOVANT | 24,500 | -4,48 % | IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints | ||
| DYNE THERAPEUTICS | 18,680 | -3,51 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) | - New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history - - Data expand on previously reported results demonstrating that... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 45,320 | -0,66 % | H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details | ||
| ZENTALIS PHARMACEUTICALS | 6,630 | +50,17 % | Jefferies raises Zentalis stock price target on ovarian cancer trial data | ||
| VERA THERAPEUTICS | 45,000 | +9,92 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |